The effect of conventional and sustained delivery of thymoquinone and levodopa on SH-SY5Y human neuroblastoma cells

Biomedical Sciences Instrumentation

Volumn 42, Issue , 2006, Pages 332-337

  Martin, Tina Mitchell ^a   Benghuzzi, Hamed ^a   Tucci, Michelle ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Drug Delivery System; Levodopa; Parkinson's disease; SH SY5Y human neuroblastoma cells; Thymoquinone

Indexed keywords

BIOMECHANICS; DISEASE CONTROL; DRUG DOSAGE; METABOLISM; NEUROLOGY; OXIDATION; PATHOLOGY; TOXICITY; INSTRUMENTS; LANDFORMS;

DRUG DELIVERY SYSTEM; LEVODOPA; PARKINSON'S DISEASE; SH-SY5Y HUMAN NEUROBLASTOMA CELLS; THYMOQUINONE;

CELL CULTURE; DRUG DELIVERY;

CALCIUM PHOSPHATE; GLUTATHIONE; LEVODOPA; QUINONE DERIVATIVE; THYMOQUINONE;

AUTOOXIDATION; CELL METABOLISM; CELL VIABILITY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; HUMAN; HUMAN CELL; INFLAMMATION; NEUROBLASTOMA CELL; NEUROPROTECTION; PARKINSON DISEASE; SUSTAINED DRUG RELEASE;

ANTIPARKINSON AGENTS; BENZOQUINONES; CELL LINE, TUMOR; CELL SURVIVAL; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; HUMANS; HYDROGEN PEROXIDE; LEVODOPA; NEUROBLASTOMA; NEUROPROTECTIVE AGENTS; TREATMENT OUTCOME;

DRUG DELIVERY SYSTEM; LEVODOPA; PARKINSON'S DISEASE; SH-SY5Y HUMAN NEUROBLASTOMA CELLS; THYMOQUINONE;

EID: 70449100461     PISSN: 00678856     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. th ed). Philadelphia: WB Saunders Company.
2. rd ed.). pp. 1502-1503. Philadelphia: Lippincott-Raven.
3. The National Parkinson Foundation, Inc. http://www.parkinson.org. Accessed on November 29, 2005.
4. Silva, M.A., Mattern, C., Hacker, R., et al. (1997). Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-dopa: on the role of benserazide pretreatment. Synapse, 27, 294-302.
5. Lang, A.E., & Lozano, A.M. (1998). Medical progress: Parkinson's disease. The New England Journal of Medicine, 339, 1130-1143.
6. Munchau, A., & Bhatia, K.P. (2000). Pharmacologic treatment in Parkinson's Disease. Postgraduate Medicine Journal, 76, 602-610.
7. Gomez-Santos, C., Ferer, I., Santididrian, A.F., Barrachina, M., Gil, J., Ambrisio, S. (2003). Dopamine induces autophagic cell death and α-synuclein increase in human neuroblastoma SH-SY5Y cells. Journal of Neuroscience Research. 73, 341-350.
8. Lai, C. & Yu, P.H. (1997). Dopamine- and L-B-3-4- dihydroxyphenylalanine hydrochloride (L-dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells. Biochemical Pharmacology, 53, 363-372.
9. Martin, T., Benghuzzi, H., and Tucci, M. (2005). The effect of conventional and sustained delivery of L-dopa on SH-SY5Y neuroblastoma cells. Biomedical Sciences Instrumentation, 41, 382-387.
10. Malisza, K.L., McIntosh, A.R., Sveinson, S.E., Hasinoff, B.B. (1996). Semiquionone free radical formation by daunorubicin aglycone incorporated into the cellular membranes of intact Chinese hamster ovary cells. Free Radical Research. 24, 9-18.
11. Houghton, P.J., Zarka, R., Heras, B.D.L., et al. (1995). Fixed oil of Nigella saliva and derived thymoquinone inhibit eicosanoid generation in leukocytes and membrane lipid peroxidation. Planta Med., 61, 33-36.
12. Mohamed, A., Shoker, A., Bendjelloul, F., et al. (2003). Improvement of experimental allergic encephalomyelitis (EAE) by thymoquinone: an oxidative stress inhibitor. Biomedical Sciences Instrumentation, 39, 440-445.
13. Takahashi, T., Maruyama, W., Deng, Y., Dostert, P., Nakahara, D., Niwa, T., Ohta, S., Naoi, M. (1997). Cytotoxicity of endogenous isoquinolines to human dopaminergic neuroblastoma SH-SY5Y cells. Journal Neural Transmission, 104, 59-66.
14. Sheehan, J.P., Palmer, P.E., Helm, G.A., and Tuttle, J.B. (1997). MPP+ induced apoptotic cell death in SH-SY5Y neuroblastoma cells: an electron microscope study. Journal Neuroscience Research, 48, 226-237.
15. Benghuzzi, H., Barbaro, R.M., & Bajpai, P.K. (1990). In vitro release of azidothymidine (AZT) by ceramic drug delivery systems. Biomedical Sciences Instrumentation, 26, 151-156.
16. Benghuzzi, H.A., England, B.G., & Bajpai, P.K. (1992). Controlled release of hydrophilic compounds by resorbable and biodegradable ceramic drug delivery devices. Biomedical Sciences Instrumentation, 28, 179-182.
17. Benghuzzi, H., England, B.G., & Bajpai, P.K. (1990). Long term delivery of testosterone by ALCAP ceramic implants in rats. Journal of Applied Biomaterials, 1, 233-240.
18. Bamosa, A.O., Ali, B.A., al-Hawsawi, Z.A. (2002). The effect of thymoquinone on blood lipids in rats. Indian Journal of Physiology and Pharmacology, 46, 195-201.
19. Mansour, M.A., Ginawi, O.T., El-Hadiyah, T., El-Khatib, A.S., Al-Shabanah, O.A., Al-Sawaf, H.A. (2001). Effects of volatile oil constituents of Nigella saliva on carbon tetrachloride-induced hepatotoxicity in mice; evidence for antioxidant effects of thymoquinone. Research Communications in Molecular Pathology and Pharmacology, 110, 239-251.
20. Mohamed, A., Shoker, A., Bendjelloul, F., et al. (2003). Improvement of experimental allergic encephalomyelitis (EAE) by thymoquinone: an oxidative stress inhibitor. Biomedical Sciences Instrumentation, 39, 440-445.
21. Mohamed, A., Afridi, D.M., Garani, O., Tucci, M. (2005). Thymoquinone inhibits the activation of NF-kappaβ in the brain and spinal cord of experimental autoimmune encephalitis. Biomedical Sciences Instrumentation, 41, 388-393.
22. Hosseinzadeh, H., Parvardeh, S., Nassiri-Asi, M., Mansouri, M. (2005). Intracerebroventricular administration of thymoquinone, the major constituent of Nigella saliva seeds, suppresses epileptic seizures in rats. Medical Science Monitor, 11, BR106-110.
23. Fahn, S., Oakes, D., Shoulson, I., Kieburtz, K., Rudolph, A., Lang, A., Olanow, C.W., Tanner, C., Marek, K.; Parkinson's Study Group (2004). Levodopa and the progression of Parkinson's disease. New England Journal of Medicine, 351, 2498-2508.